



**DIRECTORATE GENERAL HEALTH SERVICES
KHYBER PAKHTUNKHWA**


Office Phone No. 091-9210269
DGHS Fax No. 091-9210230
Exchange No. 091-9210187-96

No. 556-565/MCC
Date. 18/06/2026

OFFICE ORDER

In continuation to this office order No. 274-281/MCC dated 25/05/2026 and 546-555/MCC dated 16-06-2026, the revised Bid Evaluation Report (Technical) of Govt. MCC FY 2026-27 after rectification of the typographical/ formulary errors/omissions is hereby approved and shall be published on the official websites of Health department, KP-PPRA and EPADS.


Encl: Revised Bid Evaluation Report (Technical) Govt. MCC FY 2026-27


**Director General Health Services Khyber Pakhtunkhwa
(Chairman S&RC Committee Govt. MCC 2026-27)**

No & Date Even.

Copy for information to:

1. Additional DGHS (M&E)/Chairman T&E Committee, Govt. MCC FY 2026-27.
2. Managing Director KP-PPRA, Govt. of Khyber Pakhtunkhwa, Peshawar with the request to hoist the Revised Bid Evaluation Report (Technical) on the authority website.
3. Deputy Director IT, Health Department, Govt. of Khyber Pakhtunkhwa, to hoist/upload the Revised Bid Evaluation Report (Technical) for the medicines/drugs, surgical disposables, medical devices and non-drug items Govt. MCC FY 2026-27, on the official website (www.healthkp.gov.pk).
4. Database Administrator, Directorate General Health Services, Khyber Pakhtunkhwa, to hoist/upload the Revised Bid Evaluation Report (Technical) for the medicines/drugs, surgical disposables, medical devices and non-drug items Govt. MCC FY 2026-27, on the official website (www.dghskp.gov.pk).
5. PS to Principal Secretary to Chief Minister, Govt. of Khyber Pakhtunkhwa Peshawar.
6. PS to Director General National Accountability Bureau Khyber Pakhtunkhwa.
7. PS to Secretary Health, Govt. of Khyber Pakhtunkhwa, Peshawar.
8. PS to Minister Health, Govt. of Khyber Pakhtunkhwa, Peshawar.
9. PA to DG DC&PS, Khyber Pakhtunkhwa.
10. All applicant bidders of Govt. MCC tender FY 2026-27.


**Director General Health Services Khyber Pakhtunkhwa
(Chairman S&RC Committee Govt. MCC 2026-27)**

S. No.	Product Description	Technical Evaluation Matrix										Total Score	Weighted Score
		Product Performance Parameters					Product Safety Parameters						
		Product Performance Parameters					Product Safety Parameters					Product Quality	Product Price
1	Product A	85	90	88	82	80	92	95	93	88	85	90	85
2	Product B	90	85	88	80	85	88	92	90	85	82	88	82
3	Product C	88	82	85	80	78	85	88	86	80	75	85	80
4	Product D	82	78	80	75	72	80	82	80	75	70	80	75
5	Product E	80	75	78	72	70	78	80	78	72	68	78	72

TECHNICAL EVALUATION MATRIX FOR PROCUREMENT OF MEDICAL EQUIPMENT - HCC/IT/2024/07													
S. No.	Product Description	Technical Evaluation Parameters										Total Score	Weighted Score
		Product Performance Parameters					Product Safety Parameters						
1	Product A	85	90	88	82	80	92	95	93	88	85	90	85
2	Product B	90	85	88	80	85	88	92	90	85	82	88	82
3	Product C	88	82	85	80	78	85	88	86	80	75	85	80
4	Product D	82	78	80	75	72	80	82	80	75	70	80	75
5	Product E	80	75	78	72	70	78	80	78	72	68	78	72

TECHNICAL EVALUATION MATRIX FOR PROCUREMENT OF MEDICAL EQUIPMENT - HCC/IT/2024/07													
S. No.	Product Description	Technical Evaluation Parameters										Total Score	Weighted Score
		Product Performance Parameters					Product Safety Parameters						
1	Product A	85	90	88	82	80	92	95	93	88	85	90	85
2	Product B	90	85	88	80	85	88	92	90	85	82	88	82
3	Product C	88	82	85	80	78	85	88	86	80	75	85	80
4	Product D	82	78	80	75	72	80	82	80	75	70	80	75
5	Product E	80	75	78	72	70	78	80	78	72	68	78	72

TECHNICAL EVALUATION MATRIX FOR PROCUREMENT OF MEDICAL EQUIPMENT - HCC/IT/2024/07													
Name of the Firm with Company Address		BIDDING INFORMATION											
Manufacturer / Supplier		BIDDING											
1	Product A	85	90	88	82	80	92	95	93	88	85	90	85
2	Product B	90	85	88	80	85	88	92	90	85	82	88	82
3	Product C	88	82	85	80	78	85	88	86	80	75	85	80
4	Product D	82	78	80	75	72	80	82	80	75	70	80	75
5	Product E	80	75	78	72	70	78	80	78	72	68	78	72

TECHNICAL EVALUATION MATRIX FOR PROCUREMENT OF MEDICAL EQUIPMENT - HCC/IT/2024/07													
S. No.	Product Description	Technical Evaluation Parameters										Total Score	Weighted Score
		Product Performance Parameters					Product Safety Parameters						
1	Product A	85	90	88	82	80	92	95	93	88	85	90	85
2	Product B	90	85	88	80	85	88	92	90	85	82	88	82
3	Product C	88	82	85	80	78	85	88	86	80	75	85	80
4	Product D	82	78	80	75	72	80	82	80	75	70	80	75
5	Product E	80	75	78	72	70	78	80	78	72	68	78	72

Product Name	Model	Material	Color	Weight	Dimensions	Power	Speed	Capacity	Warranty	Price	Availability	Customer Rating	Manufacturer
Product A	Model X	Material Y	Color Z	Weight 1	Dimensions 1	Power 1	Speed 1	Capacity 1	Warranty 1	Price 1	Availability 1	Customer Rating 1	Manufacturer 1
Product B	Model Y	Material X	Color W	Weight 2	Dimensions 2	Power 2	Speed 2	Capacity 2	Warranty 2	Price 2	Availability 2	Customer Rating 2	Manufacturer 2
Product C	Model Z	Material W	Color V	Weight 3	Dimensions 3	Power 3	Speed 3	Capacity 3	Warranty 3	Price 3	Availability 3	Customer Rating 3	Manufacturer 3

Product Name		Material		Color		Weight		Dimensions		Power		Speed		Capacity		Warranty		Price		Availability		Customer Rating		Manufacturer	
1	Product A	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2
2	Product B	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2
3	Product C	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2

Product Name		Material		Color		Weight		Dimensions		Power		Speed		Capacity		Warranty		Price		Availability		Customer Rating		Manufacturer	
4	Product A	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2
5	Product B	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2
6	Product C	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2

Product Name		Material		Color		Weight		Dimensions		Power		Speed		Capacity		Warranty		Price		Availability		Customer Rating		Manufacturer	
7	Product A	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2
8	Product B	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2
9	Product C	Material X	Material Y	Color Z	Color W	Weight 1	Weight 2	Dimensions 1	Dimensions 2	Power 1	Power 2	Speed 1	Speed 2	Capacity 1	Capacity 2	Warranty 1	Warranty 2	Price 1	Price 2	Availability 1	Availability 2	Customer Rating 1	Customer Rating 2	Manufacturer 1	Manufacturer 2

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----

Industry Health - Canada

S. No.	Product Class/Description				Business Results/Key Issues										Public Outcomes/Performance										Overall Score	Weight																																																																														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24			25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100		
1	Pharmaceuticals	Generic Drugs	Patent Medicines	Biologics	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

Industry Health - Europe

S. No.	Product Class/Description				Business Results/Key Issues										Public Outcomes/Performance										Overall Score	Weight																																																																														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24			25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100		
1	Pharmaceuticals	Generic Drugs	Patent Medicines	Biologics	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

Industry Health - Australia

S. No.	Product Class/Description				Business Results/Key Issues										Public Outcomes/Performance										Overall Score	Weight																																																																														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24			25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100		
1	Pharmaceuticals	Generic Drugs	Patent Medicines	Biologics	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

K. No.	Kategori	Sub-kategori	Nama	Klasifikasi	Kondisi Kesehatan												Keterangan	Tgl. Terakhir
					1	2	3	4	5	6	7	8	9	10	11	12		
101

Kondisi Kesehatan																		
K. No.	Kategori	Sub-kategori	Nama	Klasifikasi	Kondisi Kesehatan												Keterangan	Tgl. Terakhir
					1	2	3	4	5	6	7	8	9	10	11	12		
101

Kondisi Kesehatan																		
K. No.	Kategori	Sub-kategori	Nama	Klasifikasi	Kondisi Kesehatan												Keterangan	Tgl. Terakhir
					1	2	3	4	5	6	7	8	9	10	11	12		
101

Kondisi Kesehatan																		
K. No.	Kategori	Sub-kategori	Nama	Klasifikasi	Kondisi Kesehatan												Keterangan	Tgl. Terakhir
					1	2	3	4	5	6	7	8	9	10	11	12		
101

S/N	Project Name	District	Region	Sector	Project Objectives										Total Project Investment (US\$)	Project Start Date	Project End Date	Project Status
					1	2	3	4	5	6	7	8	9	10				
101	
102	
103	

Table with 20 columns and multiple rows, containing detailed project data and financial information.

Table with 20 columns and multiple rows, containing detailed project data and financial information.

Table with 20 columns and multiple rows, containing detailed project data and financial information.

Name of the Project		Project Evaluation Metrics										Project Evaluation Results									
N. No.	Project Name	Financial Indicators					Operational Indicators					Quality Indicators					Social Indicators				
		Revenue	Cost	Profit	ROI	NPV	Efficiency	Productivity	Quality	Customer Satisfaction	Employee Satisfaction	Compliance	Health & Safety	Environmental	Community	Stakeholder	Impact	Reputation			
1	Project A	100	80	20	20%	1.2	1.5	4.5	4.8	4.2	95%	90%	98%	92%	96%	94%	97%	93%			
2	Project B	120	90	30	25%	1.3	1.6	4.6	4.9	4.3	96%	91%	99%	93%	97%	95%	98%	94%			

Table 1: Evaluation Criteria for Assessment of General Manager, Group, Period: September 2023 to December 2023

N. No.	Project Name	Financial Indicators										Operational Indicators										Quality Indicators										Social Indicators									
		Revenue	Cost	Profit	ROI	NPV	Efficiency	Productivity	Quality	Customer Satisfaction	Employee Satisfaction	Compliance	Health & Safety	Environmental	Community	Stakeholder	Impact	Reputation																							
3	Project C	150	100	50	33%	1.4	1.7	4.7	5.0	4.4	97%	92%	100%	94%	98%	96%	99%	95%																							
4	Project D	180	120	60	33%	1.5	1.8	4.8	5.1	4.5	98%	93%	100%	95%	99%	97%	100%	96%																							

Table 2: Evaluation Criteria for Assessment of General Manager, Group, Period: January 2024 to December 2024

N. No.	Project Name	Financial Indicators										Operational Indicators										Quality Indicators										Social Indicators									
		Revenue	Cost	Profit	ROI	NPV	Efficiency	Productivity	Quality	Customer Satisfaction	Employee Satisfaction	Compliance	Health & Safety	Environmental	Community	Stakeholder	Impact	Reputation																							
5	Project E	200	130	70	35%	1.6	1.9	4.9	5.2	4.6	99%	94%	100%	96%	100%	98%	100%	97%																							
6	Project F	250	150	100	40%	1.7	2.0	5.0	5.3	4.7	100%	95%	100%	97%	100%	99%	100%	98%																							

Table 3: Evaluation Criteria for Assessment of General Manager, Group, Period: January 2025 to December 2025

N. No.	Project Name	Financial Indicators										Operational Indicators										Quality Indicators										Social Indicators									
		Revenue	Cost	Profit	ROI	NPV	Efficiency	Productivity	Quality	Customer Satisfaction	Employee Satisfaction	Compliance	Health & Safety	Environmental	Community	Stakeholder	Impact	Reputation																							
7	Project G	300	180	120	40%	1.8	2.1	5.1	5.4	4.8	100%	96%	100%	98%	100%	100%	100%	99%																							
8	Project H	350	200	150	43%	1.9	2.2	5.2	5.5	4.9	100%	97%	100%	99%	100%	100%	100%	100%																							
9	Project I	400	220	180	45%	2.0	2.3	5.3	5.6	5.0	100%	98%	100%	100%	100%	100%	100%	100%																							
10	Project J	450	240	210	47%	2.1	2.4	5.4	5.7	5.1	100%	99%	100%	100%	100%	100%	100%	100%																							
11	Project K	500	260	240	48%	2.2	2.5	5.5	5.8	5.2	100%	100%	100%	100%	100%	100%	100%	100%																							
12	Project L	550	280	270	49%	2.3	2.6	5.6	5.9	5.3	100%	100%	100%	100%	100%	100%	100%	100%																							
13	Project M	600	300	300	50%	2.4	2.7	5.7	6.0	5.4	100%	100%	100%	100%	100%	100%	100%	100%																							
14	Project N	650	320	330	51%	2.5	2.8	5.8	6.1	5.5	100%	100%	100%	100%	100%	100%	100%	100%																							
15	Project O	700	340	360	51%	2.6	2.9	5.9	6.2	5.6	100%	100%	100%	100%	100%	100%	100%	100%																							
16	Project P	750	360	390	52%	2.7	3.0	6.0	6.3	5.7	100%	100%	100%	100%	100%	100%	100%	100%																							
17	Project Q	800	380	420	53%	2.8	3.1	6.1	6.4	5.8	100%	100%	100%	100%	100%	100%	100%	100%																							
18	Project R	850	400	450	53%	2.9	3.2	6.2	6.5	5.9	100%	100%	100%	100%	100%	100%	100%	100%																							
19	Project S	900	420	480	53%	3.0	3.3	6.3	6.6	6.0	100%	100%	100%	100%	100%	100%	100%	100%																							
20	Project T	950	440	510	54%	3.1	3.4	6.4	6.7	6.1	100%	100%	100%	100%	100%	100%	100%	100%																							
21	Project U	1000	460	540	54%	3.2	3.5	6.5	6.8	6.2	100%	100%	100%	100%	100%	100%	100%	100%																							

Table 4: Evaluation Criteria for Assessment of General Manager, Group, Period: January 2026 to December 2026

N. No.	Project Name	Financial Indicators										Operational Indicators										Quality Indicators										Social Indicators									
		Revenue	Cost	Profit	ROI	NPV	Efficiency	Productivity	Quality	Customer Satisfaction	Employee Satisfaction	Compliance	Health & Safety	Environmental	Community	Stakeholder	Impact	Reputation																							
22	Project V	1050	480	570	54%	3.3	3.6	6.6	6.9	6.3	100%	100%	100%	100%	100%	100%	100%	100%																							
23	Project W	1100	500	600	55%	3.4	3.7	6.7	7.0	6.4	100%	100%	100%	100%	100%	100%	100%	100%																							
24	Project X	1150	520	630	55%	3.5	3.8	6.8	7.1	6.5	100%	100%	100%	100%	100%	100%	100%	100%																							
25	Project Y	1200	540	660	55%	3.6	3.9	6.9	7.2	6.6	100%	100%	100%	100%	100%	100%	100%	100%																							
26	Project Z	1250	560	690	55%	3.7	4.0	7.0	7.3	6.7	100%	100%	100%	100%	100%	100%	100%	100%																							
27	Project AA	1300	580	720	55%	3.8	4.1	7.1	7.4	6.8	100%	100%	100%	100%	100%	100%	100%	100%																							
28	Project AB	1350	600	750	55%	3.9	4.2	7.2	7.5	6.9	100%	100%	100%	100%	100%	100%	100%	100%																							
29	Project AC	1400	620	780	56%	4.0	4.3	7.3	7.6	7.0	100%	100%	100%	100%	100%	100%	100%	100%																							
30	Project AD	1450	640	810	56%	4.1	4.4	7.4	7.7	7.1	100%	100%	100%	100%	100%	100%	100%	100%																							

Table 5: Evaluation Criteria for Assessment of General Manager, Group, Period: January 2027 to December 2027

N. No.	Project General Information					Business Model/Process Area								Business Unit Area								Product/Service Processes				Project Start Date	Last Updated Date		
	Project No.	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			21	22
001	001-001	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
002	001-002	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
003	001-003	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
004	001-004	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
005	001-005	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24

© Database Credits by Management of General Medicine, Design, Project Support Group, Strategic and IT Plans for Governance 2023, Page 27

N. No.	Project General Information					Business Model/Process Area								Business Unit Area								Product/Service Processes				Project Start Date	Last Updated Date		
	Project No.	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			21	22
001	001-001	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
002	001-002	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
003	001-003	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
004	001-004	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
005	001-005	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24

© Database Credits by Management of General Medicine, Design, Project Support Group, Strategic and IT Plans for Governance 2023, Page 27

N. No.	Project General Information					Business Model/Process Area								Business Unit Area								Product/Service Processes				Project Start Date	Last Updated Date		
	Project No.	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			21	22
001	001-001	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
002	001-002	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
003	001-003	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
004	001-004	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
005	001-005	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24

© Database Credits by Management of General Medicine, Design, Project Support Group, Strategic and IT Plans for Governance 2023, Page 27

N. No.	Project General Information					Business Model/Process Area								Business Unit Area								Product/Service Processes				Project Start Date	Last Updated Date		
	Project No.	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			21	22
001	001-001	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
002	001-002	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
003	001-003	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
004	001-004	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
005	001-005	Project Name	Phase	Region	Sub-Region	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24

Project Name	Start Date	End Date	Status	Phase	Priority	Owner	Responsible	Progress (%)	Issues	Notes
Project A	2023-01-01	2023-03-31	Completed	Phase 1	High	John Doe	Jane Smith	100	None	Successful launch.
Project B	2023-04-01	2023-06-30	In Progress	Phase 2	Medium	John Doe	Jane Smith	75	Minor	On track.
Project C	2023-07-01	2023-09-30	On Hold	Phase 1	Low	John Doe	Jane Smith	0	Major	Resource issues.
Project D	2023-10-01	2023-12-31	Planned	Phase 1	High	John Doe	Jane Smith	0	None	Preparation phase.

Project Overview		Business Objectives										Operational Objectives										Financial Objectives									
KPI	Target	Objective 1					Objective 2					Objective 3					Objective 4					Objective 5					Objective 6				
		Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD
Revenue Growth	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%
Customer Satisfaction	85%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%

Project Overview		Business Objectives										Operational Objectives										Financial Objectives									
KPI	Target	Objective 1					Objective 2					Objective 3					Objective 4					Objective 5					Objective 6				
		Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD
Revenue Growth	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%
Customer Satisfaction	85%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%

Project Overview		Business Objectives										Operational Objectives										Financial Objectives									
KPI	Target	Objective 1					Objective 2					Objective 3					Objective 4					Objective 5					Objective 6				
		Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD	Q1	Q2	Q3	Q4	YTD
Revenue Growth	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%	12%	14%	16%	15%	13%	15%	17%	14%	16%	15%
Customer Satisfaction	85%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%	80%	82%	84%	83%	81%	83%	85%	82%	84%	83%

No.	Product/Service	Category	Sub-Category	Unit	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Q21	Q22	Q23	Q24	Q25	Q26	Q27	Q28	Q29	Q30	
101	Medicine	Drug	Drug	mg	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

Evaluation Criteria for Manufacturers of General Medicine, Drug, Ready to Use Drug, Biologics and IV Fluids for Government at FY 2024-27

GENEX PHARMA S.A.S.MC/30																																			
S. No.	Product Code/Description	Brand	Generic Name	Strength	Quality Evaluation Parameters															Market Evaluation Parameters															
					Biosimilarity/Reference Product					Process/Manufacturing					Product/Performance					Market/Availability					Compliance/Regulatory										
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	
101	Amoxicillin	Amoxicillin	Amoxicillin	250mg	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

Evaluation Criteria for Manufacturers of General Medicine, Drug, Ready to Use Drug, Biologics and IV Fluids for Government at FY 2024-27

GENEX PHARMA S.A.S.MC/30																																				
S. No.	Product Code/Description	Brand	Generic Name	Strength	Quality Evaluation Parameters															Market Evaluation Parameters																
					Biosimilarity/Reference Product					Process/Manufacturing					Product/Performance					Market/Availability					Compliance/Regulatory											
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30		
101	Amoxicillin	Amoxicillin	Amoxicillin	250mg	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----

General Part - Mandatory																															
General Part - Mandatory																															
General Part - Mandatory																															
[Detailed technical specifications and data for General Part - Mandatory]																															

General Part - Mandatory																															
General Part - Mandatory																															
General Part - Mandatory																															
[Detailed technical specifications and data for General Part - Mandatory]																															

TECHNICAL EVALUATION PROGRAM FOR PRIOR REVIEW OF ANTI-CANCER MEDICINES IN GOV. M.C.C. FY 2024-27																															
TECHNICAL EVALUATION PROGRAM FOR PRIOR REVIEW OF ANTI-CANCER MEDICINES IN GOV. M.C.C. FY 2024-27																															
TECHNICAL EVALUATION PROGRAM FOR PRIOR REVIEW OF ANTI-CANCER MEDICINES IN GOV. M.C.C. FY 2024-27																															
[Detailed technical specifications and data for Technical Evaluation Program]																															

TECHNICAL EVALUATION PROGRAM FOR PRIOR REVIEW OF ANTI-CANCER MEDICINES IN GOV. M.C.C. FY 2024-27																															
TECHNICAL EVALUATION PROGRAM FOR PRIOR REVIEW OF ANTI-CANCER MEDICINES IN GOV. M.C.C. FY 2024-27																															
TECHNICAL EVALUATION PROGRAM FOR PRIOR REVIEW OF ANTI-CANCER MEDICINES IN GOV. M.C.C. FY 2024-27																															
[Detailed technical specifications and data for Technical Evaluation Program]																															

ID	Name	Type	Status	Priority	Category	Evaluation Criteria																																																																																																			
						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
100001	Project Alpha	Phase 1	Active	High	Healthcare	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

- 1. Project Name
- 2. Project ID
- 3. Project Type
- 4. Project Status
- 5. Project Priority
- 6. Project Category

Evaluation Criteria for Measurement of General Medicine, Surgery, Pediatric Surgery, Obstetrics, and IV Skills for Curriculum at MTC 2020-21

ID	Name	Type	Status	Priority	Category	General Medicine										Surgery										Pediatric Surgery										Obstetrics										IV Skills																																																											
						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
100001	Project Alpha	Phase 1	Active	High	Healthcare	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

ID	Name	Type	Status	Priority	Category	General Medicine										Surgery										Pediatric Surgery										Obstetrics										IV Skills																																																											
						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
100001	Project Alpha	Phase 1	Active	High	Healthcare	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

No. No.	Project General Information				Project Technical Parameters										Project Financial Parameters																
	Project Name	Location	Contract No.	Contract Value	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
1

No. No.	Project General Information				Project Technical Parameters										Project Financial Parameters																
	Project Name	Location	Contract No.	Contract Value	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
2

No. No.	Project General Information				Project Technical Parameters										Project Financial Parameters																
	Project Name	Location	Contract No.	Contract Value	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
3

No. No.	Project General Information				Project Technical Parameters										Project Financial Parameters																
	Project Name	Location	Contract No.	Contract Value	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
4

S. No.	Product Category/Description	General Information				Technical Evaluation Criteria																			Total Score			
		1	2	3	4	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		20	21	22
1	General Medicines	1	2	3	4	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
2	Drugs	1	2	3	4	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
3	Parental Injectable Drugs	1	2	3	4	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
4	Sterile Ophthalmics	1	2	3	4	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
5	IV Fluids	1	2	3	4	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23

Table 2. Evaluation Criteria for Manufacturers of General Medicines, Drugs, Parental Injectable Drugs, Sterile Ophthalmics and IV Fluids for Coronavirus (NCoV-2019)

S. No.	Product Category/Description	Technical Evaluation Criteria																			Total Score							
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		20	21	22	23			
1	General Medicines	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
2	Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
3	Parental Injectable Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
4	Sterile Ophthalmics	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
5	IV Fluids	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27

Table 3. Evaluation Criteria for Manufacturers of General Medicines, Drugs, Parental Injectable Drugs, Sterile Ophthalmics and IV Fluids for Coronavirus (NCoV-2019)

S. No.	Product Category/Description	Technical Evaluation Criteria																			Total Score							
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		20	21	22	23			
1	General Medicines	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
2	Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
3	Parental Injectable Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
4	Sterile Ophthalmics	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
5	IV Fluids	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27

Table 4. Evaluation Criteria for Manufacturers of General Medicines, Drugs, Parental Injectable Drugs, Sterile Ophthalmics and IV Fluids for Coronavirus (NCoV-2019)

S. No.	Product Category/Description	Technical Evaluation Criteria																			Total Score							
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		20	21	22	23			
1	General Medicines	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
2	Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
3	Parental Injectable Drugs	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
4	Sterile Ophthalmics	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
5	IV Fluids	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27

Kategori		Evaluasi Kinerja Berdasarkan Indikator Kinerja Utama (IKU) dan Indikator Kinerja Tambahan (IKT)										Evaluasi Kinerja Berdasarkan Indikator Kinerja Tambahan (IKT)														
No.	Nama	Indikator Kinerja Utama (IKU)					Indikator Kinerja Tambahan (IKT)					Indikator Kinerja Tambahan (IKT)					Indikator Kinerja Tambahan (IKT)									
		1	2	3	4	5	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5					
1																										
2																										
3																										
4																										

Kategori		Evaluasi Kinerja Berdasarkan Indikator Kinerja Utama (IKU) dan Indikator Kinerja Tambahan (IKT)										Evaluasi Kinerja Berdasarkan Indikator Kinerja Tambahan (IKT)														
No.	Nama	Indikator Kinerja Utama (IKU)					Indikator Kinerja Tambahan (IKT)					Indikator Kinerja Tambahan (IKT)					Indikator Kinerja Tambahan (IKT)									
		1	2	3	4	5	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5					
1																										
2																										
3																										
4																										
5																										
6																										
7																										
8																										
9																										
10																										

Kategori		Evaluasi Kinerja Berdasarkan Indikator Kinerja Utama (IKU) dan Indikator Kinerja Tambahan (IKT)										Evaluasi Kinerja Berdasarkan Indikator Kinerja Tambahan (IKT)														
No.	Nama	Indikator Kinerja Utama (IKU)					Indikator Kinerja Tambahan (IKT)					Indikator Kinerja Tambahan (IKT)					Indikator Kinerja Tambahan (IKT)									
		1	2	3	4	5	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5					
1																										
2																										
3																										
4																										
5																										
6																										
7																										
8																										
9																										
10																										

Kategori		Evaluasi Kinerja Berdasarkan Indikator Kinerja Utama (IKU) dan Indikator Kinerja Tambahan (IKT)										Evaluasi Kinerja Berdasarkan Indikator Kinerja Tambahan (IKT)														
No.	Nama	Indikator Kinerja Utama (IKU)					Indikator Kinerja Tambahan (IKT)					Indikator Kinerja Tambahan (IKT)					Indikator Kinerja Tambahan (IKT)									
		1	2	3	4	5	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5					
1																										
2																										
3																										
4																										
5																										
6																										
7																										
8																										
9																										
10																										

Project Name	Year	Status	Phase	Key Indicators												
				K1	K2	K3	K4	K5	K6	K7	K8	K9	K10			
Project A	2023	Completed	Phase 1	1.2	0.8	1.5	0.5	1.8	0.3	1.0	0.9	1.1	0.7	1.3	0.6	1.4
Project B	2023	Ongoing	Phase 2	1.5	1.0	1.8	0.6	2.1	0.4	1.2	1.0	1.3	0.8	1.6	0.7	1.5
Project C	2023	Completed	Phase 3	1.0	0.7	1.4	0.4	1.7	0.5	1.1	0.8	1.2	0.6	1.5	0.5	1.4
Project D	2023	Ongoing	Phase 1	1.3	0.9	1.6	0.5	1.9	0.4	1.1	0.9	1.3	0.7	1.7	0.6	1.6
Project E	2023	Completed	Phase 2	1.1	0.8	1.5	0.4	1.8	0.5	1.0	0.7	1.2	0.6	1.4	0.5	1.3

Project Details		Project Objectives												Performance Indicators												Overall Status											
Project ID	Project Name	Objective 1				Objective 2				Objective 3				Objective 4				Indicator 1				Indicator 2				Phase	Status	Start	End								
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4												
101	Project A	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	Phase 1	Completed	2023	2024
102	Project B	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	Phase 2	Ongoing	2023	2024

Table for Monitoring of General Methods, Usage, and Quality Indicators

Project ID	Project Name	Methodology				Quality Indicators												Phase	Status												
		1	2	3	4	Indicator Group 1						Indicator Group 2																			
						1	2	3	4	5	6	1	2	3	4	5	6														
103	Project C	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	Phase 3	Completed
104	Project D	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	Phase 1	Ongoing

Table for Agency Results

Project ID	Project Name	Agency Results				Performance Indicators												Phase	Status												
		1	2	3	4	Indicator Group 1						Indicator Group 2																			
						1	2	3	4	5	6	1	2	3	4	5	6														
105	Project E	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	Phase 2	Ongoing

Project Name	Year	Phase	Priority	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Project 1	2021	Phase A	High	5	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 2	2021	Phase B	Medium	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 3	2021	Phase C	Low	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 4	2021	Phase D	High	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 5	2021	Phase E	Medium	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 6	2021	Phase F	Low	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 7	2021	Phase G	High	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 8	2021	Phase H	Medium	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 9	2021	Phase I	Low	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 10	2021	Phase J	High	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 11	2021	Phase K	Medium	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 12	2021	Phase L	Low	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 13	2021	Phase M	High	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 14	2021	Phase N	Medium	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 15	2021	Phase O	Low	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 16	2021	Phase P	High	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 17	2021	Phase Q	Medium	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 18	2021	Phase R	Low	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 19	2021	Phase S	High	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Project 20	2021	Phase T	Medium	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Project Information				Financial Performance Indicators																					
S/N	Project Name	Phase	Priority	Quarterly Performance										Annual Performance											
				Q1	Q2	Q3	Q4	YTD	Variance	Target	Actual	Q1	Q2	Q3	Q4	YTD	Variance	Target	Actual	Q1	Q2	Q3	Q4	YTD	Variance
1	Project A	Phase 1	High	10	8	6	4	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2	Project B	Phase 2	Medium	8	7	5	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3	Project C	Phase 3	Low	6	5	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	Project D	Phase 4	High	9	7	5	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5	Project E	Phase 5	Medium	7	6	4	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
6	Project F	Phase 6	Low	5	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	Project G	Phase 7	High	8	6	4	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	Project H	Phase 8	Medium	6	5	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	Project I	Phase 9	Low	4	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	Project J	Phase 10	High	7	5	3	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Name of the Drug / Trade Name		Kulluk Pharmaceutical Kuralsi											
Trade Name	Generic Name	Section I: Quality						Section II: Safety					
		1	2	3	4	5	6	7	8	9	10	11	12
Kulluk	Tablet	1	2	3	4	5	6	7	8	9	10	11	12
	Injection	1	2	3	4	5	6	7	8	9	10	11	12
	Suspension	1	2	3	4	5	6	7	8	9	10	11	12
	Other	1	2	3	4	5	6	7	8	9	10	11	12

Section III: Environmental and Safety												
Product Description			Environmental Protection					Safety				
			<p>Environmental Protection: Measures taken to prevent pollution, waste management, and use of hazardous substances.</p>					<p>Safety: Information on risks, toxicity, and safety measures for handling and use.</p>				
			<p>Safety: Additional safety information, including first aid measures and special precautions.</p>									

Section IV: Regulatory and Compliance												
Detailed Regulatory Information and Compliance Status												
1	2	3	4	5	6	7	8	9	10	11	12	13
1	2	3	4	5	6	7	8	9	10	11	12	13
1	2	3	4	5	6	7	8	9	10	11	12	13
1	2	3	4	5	6	7	8	9	10	11	12	13

Section V: Batch Production Record (BPR) Summary												
General Information			Production Details					Quality Control				
Batch No.	Date	Plant	Material Usage					Testing Results				
1001	2023-01-01	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1002	2023-01-02	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1003	2023-01-03	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1004	2023-01-04	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1005	2023-01-05	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1006	2023-01-06	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1007	2023-01-07	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1008	2023-01-08	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1009	2023-01-09	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1010	2023-01-10	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1011	2023-01-11	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1012	2023-01-12	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1013	2023-01-13	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1014	2023-01-14	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1015	2023-01-15	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1016	2023-01-16	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1017	2023-01-17	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1018	2023-01-18	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1019	2023-01-19	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9
1020	2023-01-20	Plant A	1.2	1.5	1.8	2.1	2.4	2.7	3.0	3.3	3.6	3.9

Section VI: Summary and Final Review												
Product Overview			Compliance Status					Final Approval				
1	2	3	4	5	6	7	8	9	10	11	12	13
1	2	3	4	5	6	7	8	9	10	11	12	13

Sl. No.	Name of the Institution	Address	City	State	Pin Code	Date of establishment	A) Infrastructure				B) Academic Quality				C) Faculty				D) Student Welfare				Overall Rating	Remarks				
							1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16			17	18	19	20
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
2	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
3	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
4	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
5	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
6	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
7	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
8	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
9	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
10	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22

Evaluation criteria for Measurement of General Medicine, Surgery, Postgraduate Degree, Bachelors and IV Rank for Government MCY 2020-21

Sl. No.	Name of the Institution	Address	City	State	Pin Code	Date of establishment	A) Infrastructure				B) Academic Quality				C) Faculty				D) Student Welfare				Overall Rating	Remarks				
							1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16			17	18	19	20
11	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
12	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
13	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
14	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
15	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
16	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
17	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
18	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
19	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22

Evaluation criteria for Measurement of General Medicine, Surgery, Postgraduate Degree, Bachelors and IV Rank for Government MCY 2020-21

Sl. No.	Name of the Institution	Address	City	State	Pin Code	Date of establishment	A) Infrastructure				B) Academic Quality				C) Faculty				D) Student Welfare				Overall Rating	Remarks				
							1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16			17	18	19	20
20	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
21	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
22	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
23	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
24	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
25	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
26	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
27	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
28	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22

Evaluation criteria for Measurement of General Medicine, Surgery, Postgraduate Degree, Bachelors and IV Rank for Government MCY 2020-21

Sl. No.	Name of the Institution	Address	City	State	Pin Code	Date of establishment	A) Infrastructure				B) Academic Quality				C) Faculty				D) Student Welfare				Overall Rating	Remarks				
							1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16			17	18	19	20
29	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
30	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
31	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
32	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
33	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
34	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
35	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22

Evaluation criteria for Measurement of General Medicine, Surgery, Postgraduate Degree, Bachelors and IV Rank for Government MCY 2020-21

No.	Project Name	Project ID	Project Type	Project Status	Project Performance Indicators												Total Score	Weighted Score
					1	2	3	4	5	6	7	8	9	10	11	12		
1	Project A	PA001	Construction	Completed	95	90	85	80	75	70	65	60	55	50	45	40	35	30
2	Project B	PB002	IT Development	In Progress	88	82	77	72	67	62	57	52	47	42	37	32	27	22
3	Project C	PC003	Manufacturing	On Hold	70	65	60	55	50	45	40	35	30	25	20	15	10	5
4	Project D	PD004	Research & Dev	Planning	60	55	50	45	40	35	30	25	20	15	10	5	0	0

Table 1: Summary of Project Performance Indicators (Q1-Q4 2023)

No.	Project Name	Project ID	Project Type	Project Status	Project Performance Indicators												Total Score	Weighted Score
					1	2	3	4	5	6	7	8	9	10	11	12		
5	Project E	PE005	Construction	Completed	92	87	82	77	72	67	62	57	52	47	42	37	32	27
6	Project F	PF006	IT Development	In Progress	85	80	75	70	65	60	55	50	45	40	35	30	25	20
7	Project G	PG007	Manufacturing	On Hold	68	63	58	53	48	43	38	33	28	23	18	13	8	3
8	Project H	PH008	Research & Dev	Planning	58	53	48	43	38	33	28	23	18	13	8	3	0	0
9	Project I	PI009	Construction	Completed	90	85	80	75	70	65	60	55	50	45	40	35	30	25
10	Project J	PJ010	IT Development	In Progress	82	77	72	67	62	57	52	47	42	37	32	27	22	17
11	Project K	PK011	Manufacturing	On Hold	65	60	55	50	45	40	35	30	25	20	15	10	5	0
12	Project L	PL012	Research & Dev	Planning	55	50	45	40	35	30	25	20	15	10	5	0	0	0

Table 2: Summary of Project Performance Indicators (Q1-Q4 2023)

No.	Project Name	Project ID	Project Type	Project Status	Project Performance Indicators												Total Score	Weighted Score
					1	2	3	4	5	6	7	8	9	10	11	12		
13	Project M	PM013	Construction	Completed	88	83	78	73	68	63	58	53	48	43	38	33	28	23
14	Project N	PN014	IT Development	In Progress	80	75	70	65	60	55	50	45	40	35	30	25	20	15
15	Project O	PO015	Manufacturing	On Hold	62	57	52	47	42	37	32	27	22	17	12	7	2	0
16	Project P	PP016	Research & Dev	Planning	52	47	42	37	32	27	22	17	12	7	2	0	0	0
17	Project Q	PQ017	Construction	Completed	85	80	75	70	65	60	55	50	45	40	35	30	25	20
18	Project R	PR018	IT Development	In Progress	78	73	68	63	58	53	48	43	38	33	28	23	18	13
19	Project S	PS019	Manufacturing	On Hold	60	55	50	45	40	35	30	25	20	15	10	5	0	0
20	Project T	PT020	Research & Dev	Planning	50	45	40	35	30	25	20	15	10	5	0	0	0	0

Product	Code	Quantity	Value	Origin	Country	HS Code	HTS Code	Product Description	Year	Month	Day	Hour	Minute	Second	Millisecond	Microsecond	Nanosecond	Picosecond	Femtosecond	Attosecond	Zeptosecond	Yoctosecond
...
...
...

Product Details			Quantity & Value			Origin		Country		HS Code		HTS Code		Product Description		Year		Month		Day		Hour		Minute		Second		Millisecond		Microsecond		Nanosecond		Picosecond		Femtosecond		Attosecond		Zeptosecond		Yoctosecond								
Product A	100	10000	100	10000	USA	USA	8410	8410.10	8410.10.00	8410.10.0000				
Product B	200	20000	200	20000	China	China	8410	8410.90	8410.90.00	8410.90.0000

DECLARATION OF EXPORTER FOR EXPORTATION OF MERCHANDISE BY AIR

EXPORTER'S DECLARATION

Signature of the Person in Charge: _____

Name of the Person in Charge: _____

Address of the Person in Charge: _____

Date: _____

IMPORTER'S DECLARATION

Signature of the Person in Charge: _____

Name of the Person in Charge: _____

Address of the Person in Charge: _____

Date: _____

No.	Nama Perikanan	Lokasi	Kategori	Kondisi	Penilaian Mutu										Rata-rata	Kategori Mutu	Sesuai Standar	Tingkat Kepuasan
					1	2	3	4	5	6	7	8	9	10				
1	Perikanan																	
2	Perikanan																	

Tabel 1.1.1. Mutu Produk Perikanan

No.	Produk Perikanan				Mutu Produk Perikanan										Rata-rata	Kategori Mutu	Sesuai Standar	Tingkat Kepuasan	
	No.	Nama Perikanan	Lokasi	Kategori	Kualitas Fisik					Kualitas Kimia									Rata-rata
					1	2	3	4	5	1	2	3	4	5					
1	Perikanan																		

Tabel 1.1.2. Mutu Produk Perikanan

No.	Produk Perikanan				Mutu Produk Perikanan										Rata-rata	Kategori Mutu	Sesuai Standar	Tingkat Kepuasan	
	No.	Nama Perikanan	Lokasi	Kategori	Kualitas Fisik					Kualitas Kimia									Rata-rata
					1	2	3	4	5	1	2	3	4	5					
1	Perikanan																		

Tabel 1.1.3. Mutu Produk Perikanan

Sl. No.	S.N.	Project General Information		Technical Evaluation Merit																								Project Rank	Total Weighted Marks				
				Project Objectives / Parameters												Project Technical Parameters																	
				Project Objectives / Parameters						Project Technical Parameters						Project Objectives / Parameters						Project Technical Parameters											
1	001

4

Sl. No.	S.N.	Project General Information		Technical Evaluation Merit																								Project Rank	Total Weighted Marks				
				Project Objectives / Parameters												Project Technical Parameters																	
				Project Objectives / Parameters						Project Technical Parameters						Project Objectives / Parameters						Project Technical Parameters											
...

Sl. No.	S.N.	Project General Information		Technical Evaluation Merit																								Project Rank	Total Weighted Marks				
				Project Objectives / Parameters												Project Technical Parameters																	
				Project Objectives / Parameters						Project Technical Parameters						Project Objectives / Parameters						Project Technical Parameters											
...

TECHNICAL EVALUATION PROGRAM FOR PURCHASE OF ANTI-CANCER MEDICINE IN GOVT'S 2024-27						
Name of the Bidder / Supplier						
Mandatory Requirements						
1
2
3

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----

Name of Item		Product Description		Quantity		Unit Price		Total Price		Tax		Net Price		Gross Price		Net Weight		Gross Weight		Volume		Material Code		Material Name		Material Specification		Material Grade		Material Standard		Material Test		Material Certificate		Material Approval		Material Status		Material Date		Material Location		Material Remark																																																							
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

Name of Item		Product Description		Quantity		Unit Price		Total Price		Tax		Net Price		Gross Price		Net Weight		Gross Weight		Volume		Material Code		Material Name		Material Specification		Material Grade		Material Standard		Material Test		Material Certificate		Material Approval		Material Status		Material Date		Material Location		Material Remark																																																							
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

Name of Item		Product Description		Quantity		Unit Price		Total Price		Tax		Net Price		Gross Price		Net Weight		Gross Weight		Volume		Material Code		Material Name		Material Specification		Material Grade		Material Standard		Material Test		Material Certificate		Material Approval		Material Status		Material Date		Material Location		Material Remark																																																							
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

Name of Item		Product Description		Quantity		Unit Price		Total Price		Tax		Net Price		Gross Price		Net Weight		Gross Weight		Volume		Material Code		Material Name		Material Specification		Material Grade		Material Standard		Material Test		Material Certificate		Material Approval		Material Status		Material Date		Material Location		Material Remark																																																							
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

K.Nr.	Kategorie	Bezeichnung	Einheit	Menge	Preis	Menge																			
						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1	1			

Kategorie		Bezeichnung		Menge		Preis		Menge																			
1	1				

K.Nr.	Kategorie	Bezeichnung	Einheit	Menge	Preis	Menge																			
						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1	1		

S. No.	Manufacturer Name	Generic Name	Strength	Dosage Form	Reference	Bioequivalence		Dissolution		Stability		Packaging		Labeling		Quality Control		GMP		Compliance	
						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
1	ABC Pharma	Paracetamol	500mg	Tablet	XYZ123																
2	DEF Pharma	Paracetamol	500mg	Tablet	ABC456																
3	GHI Pharma	Paracetamol	500mg	Tablet	DEF789																
4	JKL Pharma	Paracetamol	500mg	Tablet	GHI012																
5	MNO Pharma	Paracetamol	500mg	Tablet	JKL345																
6	PQR Pharma	Paracetamol	500mg	Tablet	MNO678																
7	STU Pharma	Paracetamol	500mg	Tablet	PQR901																
8	VWX Pharma	Paracetamol	500mg	Tablet	STU234																
9	YZA Pharma	Paracetamol	500mg	Tablet	VWX567																
10	BCD Pharma	Paracetamol	500mg	Tablet	YZA890																
11	EFG Pharma	Paracetamol	500mg	Tablet	BCD123																
12	HIJ Pharma	Paracetamol	500mg	Tablet	EFG456																
13	KLM Pharma	Paracetamol	500mg	Tablet	HIJ789																
14	NOP Pharma	Paracetamol	500mg	Tablet	KLM012																
15	QRS Pharma	Paracetamol	500mg	Tablet	NOP345																
16	TUV Pharma	Paracetamol	500mg	Tablet	QRS678																
17	WXY Pharma	Paracetamol	500mg	Tablet	TUV901																
18	ZAB Pharma	Paracetamol	500mg	Tablet	WXY234																
19	CDE Pharma	Paracetamol	500mg	Tablet	ZAB567																
20	FGH Pharma	Paracetamol	500mg	Tablet	CDE890																
21	IKL Pharma	Paracetamol	500mg	Tablet	FGH123																
22	MNO Pharma	Paracetamol	500mg	Tablet	IKL456																
23	PQR Pharma	Paracetamol	500mg	Tablet	MNO789																
24	STU Pharma	Paracetamol	500mg	Tablet	PQR012																
25	VWX Pharma	Paracetamol	500mg	Tablet	STU345																
26	YZA Pharma	Paracetamol	500mg	Tablet	VWX678																
27	BCD Pharma	Paracetamol	500mg	Tablet	YZA901																
28	EFG Pharma	Paracetamol	500mg	Tablet	BCD234																
29	HIJ Pharma	Paracetamol	500mg	Tablet	EFG567																
30	KLM Pharma	Paracetamol	500mg	Tablet	HIJ890																
31	NOP Pharma	Paracetamol	500mg	Tablet	KLM123																
32	QRS Pharma	Paracetamol	500mg	Tablet	NOP456																
33	TUV Pharma	Paracetamol	500mg	Tablet	QRS789																
34	WXY Pharma	Paracetamol	500mg	Tablet	TUV012																
35	ZAB Pharma	Paracetamol	500mg	Tablet	WXY345																
36	CDE Pharma	Paracetamol	500mg	Tablet	ZAB678																
37	FGH Pharma	Paracetamol	500mg	Tablet	CDE901																
38	IKL Pharma	Paracetamol	500mg	Tablet	FGH234																
39	MNO Pharma	Paracetamol	500mg	Tablet	IKL567																
40	PQR Pharma	Paracetamol	500mg	Tablet	MNO890																
41	STU Pharma	Paracetamol	500mg	Tablet	PQR123																
42	VWX Pharma	Paracetamol	500mg	Tablet	STU456																
43	YZA Pharma	Paracetamol	500mg	Tablet	VWX789																
44	BCD Pharma	Paracetamol	500mg	Tablet	YZA012																
45	EFG Pharma	Paracetamol	500mg	Tablet	BCD345																
46	HIJ Pharma	Paracetamol	500mg	Tablet	EFG678																
47	KLM Pharma	Paracetamol	500mg	Tablet	HIJ901																
48	NOP Pharma	Paracetamol	500mg	Tablet	KLM234																
49	QRS Pharma	Paracetamol	500mg	Tablet	NOP567																
50	TUV Pharma	Paracetamol	500mg	Tablet	QRS890																
51	WXY Pharma	Paracetamol	500mg	Tablet	TUV123																
52	ZAB Pharma	Paracetamol	500mg	Tablet	WXY456																
53	CDE Pharma	Paracetamol	500mg	Tablet	ZAB789																
54	FGH Pharma	Paracetamol	500mg	Tablet	CDE012																
55	IKL Pharma	Paracetamol	500mg	Tablet	FGH345																
56	MNO Pharma	Paracetamol	500mg	Tablet	IKL678																
57	PQR Pharma	Paracetamol	500mg	Tablet	MNO901																
58	STU Pharma	Paracetamol	500mg	Tablet	PQR234																
59	VWX Pharma	Paracetamol	500mg	Tablet	STU567																
60	YZA Pharma	Paracetamol	500mg	Tablet	VWX890																
61	BCD Pharma	Paracetamol	500mg	Tablet	YZA123																
62	EFG Pharma	Paracetamol	500mg	Tablet	BCD456																
63	HIJ Pharma	Paracetamol	500mg	Tablet	EFG789																
64	KLM Pharma	Paracetamol	500mg	Tablet	HIJ012																
65	NOP Pharma	Paracetamol	500mg	Tablet	KLM345																
66	QRS Pharma	Paracetamol	500mg	Tablet	NOP678																
67	TUV Pharma	Paracetamol	500mg	Tablet	QRS901																
68	WXY Pharma	Paracetamol	500mg	Tablet	TUV234																
69	ZAB Pharma	Paracetamol	500mg	Tablet	WXY567																
70	CDE Pharma	Paracetamol	500mg	Tablet	ZAB890																
71	FGH Pharma	Paracetamol	500mg	Tablet	CDE123																
72	IKL Pharma	Paracetamol	500mg	Tablet	FGH456																
73	MNO Pharma	Paracetamol	500mg	Tablet	IKL789																
74	PQR Pharma	Paracetamol	500mg	Tablet	MNO012																
75	STU Pharma	Paracetamol	500mg	Tablet	PQR345																
76	VWX Pharma	Paracetamol	500mg	Tablet	STU678																
77	YZA Pharma	Paracetamol	500mg	Tablet	VWX901																
78	BCD Pharma	Paracetamol	500mg	Tablet	YZA234																
79	EFG Pharma	Paracetamol	500mg	Tablet	BCD567																
80	HIJ Pharma	Paracetamol	500mg	Tablet	EFG890																
81	KLM Pharma	Paracetamol	500mg	Tablet	HIJ123																
82	NOP Pharma	Paracetamol	500mg	Tablet	KLM456																
83	QRS Pharma	Paracetamol	500mg	Tablet	NOP789																
84	TUV Pharma	Paracetamol	500mg	Tablet	QRS012																
85	WXY Pharma	Paracetamol	500mg	Tablet	TUV345																
86	ZAB Pharma	Paracetamol	500mg	Tablet	WXY678																

Code	Project Name	Year	Amount	Source	Priority	Category	Sub-category	Activity	Start Date	End Date	Progress %	Remarks
1001	Project A	2023	10000	Source 1	High	Category 1	Sub-category 1	Activity 1	2023-01-01	2023-12-31	100	Completed
1002	Project B	2023	20000	Source 2	Medium	Category 2	Sub-category 2	Activity 2	2023-01-01	2023-12-31	100	Completed
1003	Project C	2023	30000	Source 3	Low	Category 3	Sub-category 3	Activity 3	2023-01-01	2023-12-31	100	Completed
1004	Project D	2023	40000	Source 4	High	Category 4	Sub-category 4	Activity 4	2023-01-01	2023-12-31	100	Completed
1005	Project E	2023	50000	Source 5	Medium	Category 5	Sub-category 5	Activity 5	2023-01-01	2023-12-31	100	Completed
1006	Project F	2023	60000	Source 6	Low	Category 6	Sub-category 6	Activity 6	2023-01-01	2023-12-31	100	Completed
1007	Project G	2023	70000	Source 7	High	Category 7	Sub-category 7	Activity 7	2023-01-01	2023-12-31	100	Completed
1008	Project H	2023	80000	Source 8	Medium	Category 8	Sub-category 8	Activity 8	2023-01-01	2023-12-31	100	Completed
1009	Project I	2023	90000	Source 9	Low	Category 9	Sub-category 9	Activity 9	2023-01-01	2023-12-31	100	Completed
1010	Project J	2023	100000	Source 10	High	Category 10	Sub-category 10	Activity 10	2023-01-01	2023-12-31	100	Completed

Annual Summary Report												
Code	Project Name	Year	Amount	Source	Priority	Category	Sub-category	Activity	Start Date	End Date	Progress %	Remarks
1001-1010	Projects A-J	2023	500000	Various	High	Various	Various	Various	2023-01-01	2023-12-31	100	All completed

Code	Project Name	Year	Amount	Source	Priority	Category	Sub-category	Activity	Start Date	End Date	Progress %	Remarks
1011	Project K	2023	110000	Source 11	High	Category 11	Sub-category 11	Activity 11	2023-01-01	2023-12-31	100	Completed
1012	Project L	2023	120000	Source 12	Medium	Category 12	Sub-category 12	Activity 12	2023-01-01	2023-12-31	100	Completed
1013	Project M	2023	130000	Source 13	Low	Category 13	Sub-category 13	Activity 13	2023-01-01	2023-12-31	100	Completed
1014	Project N	2023	140000	Source 14	High	Category 14	Sub-category 14	Activity 14	2023-01-01	2023-12-31	100	Completed
1015	Project O	2023	150000	Source 15	Medium	Category 15	Sub-category 15	Activity 15	2023-01-01	2023-12-31	100	Completed
1016	Project P	2023	160000	Source 16	Low	Category 16	Sub-category 16	Activity 16	2023-01-01	2023-12-31	100	Completed
1017	Project Q	2023	170000	Source 17	High	Category 17	Sub-category 17	Activity 17	2023-01-01	2023-12-31	100	Completed
1018	Project R	2023	180000	Source 18	Medium	Category 18	Sub-category 18	Activity 18	2023-01-01	2023-12-31	100	Completed
1019	Project S	2023	190000	Source 19	Low	Category 19	Sub-category 19	Activity 19	2023-01-01	2023-12-31	100	Completed
1020	Project T	2023	200000	Source 20	High	Category 20	Sub-category 20	Activity 20	2023-01-01	2023-12-31	100	Completed

Annual Summary Report (Continued)												
Code	Project Name	Year	Amount	Source	Priority	Category	Sub-category	Activity	Start Date	End Date	Progress %	Remarks
1011-1020	Projects K-T	2023	1500000	Various	High	Various	Various	Various	2023-01-01	2023-12-31	100	All completed

